HMGCR and heart failure: The major class of hypolipidemic drugs, namely 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), reduced heart failure incidence in both primary and secondary prevention trials [34] and decreased hospitalizations for heart failure during follow-up for 15 years of the West of Scotland Primary Prevention Study [35].